Immunization of Humans with Recombinant Pneumococcal Surface Protein A (rPspA) Elicits Antibodies That Passively Protect Mice from Fatal Infection withStreptococcus pneumoniaeBearing Heterologous PspA

Citations Over TimeTop 10% of 2000 papers

Abstract

Pneumococcal surface protein A (PspA), a cross-reactive protein expressed by all pneumococci, is known to elicit an antibody in animals that can passively protect mice from infection with Streptococcus pneumoniae. A phase I trial with recombinant PspA showed the protein to be immunogenic in humans. Pre- and postimmune serum samples from this trial were examined, and human antibody to PspA could protect mice from pneumococcal infection. The serum samples of subjects immunized twice with 125 microg of PspA had >100 times as much antibody per milliliter as was required to consistently protect mice from fatal infection (1.3 microg/dose). At least 98% of PspAs fall into PspA sequence/serologic families 1 or 2. Human antibodies elicited by a family 1 PspA protected against infection with S. pneumoniae expressing either family 1 or 2 PspAs and with strains of all 3 capsular types tested: 3, 6A, and 6B. These studies suggest that PspA may have efficacy as a human vaccine.

Related Papers

• → Pneumococcal Surface Protein C Contributes to Sepsis Caused byStreptococcus pneumoniaein Mice(2004)77 cited
• → The Ongoing Genetic Adaptation of Streptococcus pneumoniae(2017)11 cited
• → Conjugative transfer of multiple antibiotic resistance markers in Streptococcus pneumoniae(1980)85 cited
• → Streptococcus pneumoniae Isolates from Middle Ear Fluid and Nasopharynx of Children with Acute Otitis Media Exhibit Phase Variation(2011)34 cited
• → Use of 2 pneumococcal common protein real-time polymerase chain reaction assays in healthy children colonized with Streptococcus pneumoniae(2011)15 cited